People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

Kelsey Warren KWarren6@its.jnj.com  609 218 4053 Investor contact: Lauren Johnson investor-relations@its.jnj.com ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

SPRAVATO ® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain. 6 The mechanism by which esketamine exerts its antidepressant effect is ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has expanded ...